News Conference News AHA 2022 ‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge L.A. McKeown November 11, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2021 Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data Yael L. Maxwell November 15, 2021
News Conference News AHA 2020 One in Five Patients Admitted With COVID-19 Die in the Hospital Michael O'Riordan November 20, 2020
News Conference News AHA 2020 Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib Todd Neale November 14, 2020
News Conference News AHA 2020 Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS Michael O'Riordan November 14, 2020
News Conference News AHA 2019 Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS Todd Neale November 20, 2019
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2015 Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants Yael L. Maxwell November 10, 2015
News Conference News AHA 2014 ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders Yael L. Maxwell November 15, 2014